Shilpa Medicare Limited — Important, 27-12-2024: General Updates

Shilpa Medicare Limited's Unit IV in Jadcherla and Unit VII in Nacharam, Hyderabad, have successfully received GMP approval from the Eurasian Economic Union (EAEU) following an inspection by the Ministry of Health, Belarus. This approval signifies compliance with quality standards and opens new business avenues in member countries including Belarus, Russia, Kazakhstan, Kyrgyzstan, and Armenia.

Unit IV focuses on the manufacture and distribution of sterile injectables and non-sterile oral dosage forms for global markets, while Unit VII engages in the testing of raw and finished materials. This strategic development positions Shilpa Medicare to enhance its market presence and capitalize on growth opportunities in the expanding EAEU market. Positive outlook as these approvals can lead to increased revenue streams and bolster international partnerships.